Announcement

Collapse
No announcement yet.

USA - High prevalence of CRE in Washington, D.C. healthcare facilities

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • USA - High prevalence of CRE in Washington, D.C. healthcare facilities

    Combatting antibiotic-resistant infections

    Date: June 15, 2017

    Source: Society for Healthcare Epidemiology of America

    Summary: Carbapenem-resistant Enterobacteriaceae (CRE), a family of highly pathogenic antibiotic-resistant organisms, are endemic across Washington, D.C. healthcare facilities, with 5.2 percent of inpatients testing positive for the bacteria, according to new research.

    Carbapenem-resistant Enterobacteriaceae (CRE), a family of highly pathogenic antibiotic-resistant organisms, are endemic across Washington, D.C. healthcare facilities, with 5.2% of inpatients testing positive for the bacteria, according to new research published online today in Infection Control & Hospital Epidemiology, the journal of the Society for Healthcare Epidemiology of America. This study, determining a regional baseline prevalence of the often-deadly superbug among inpatients, is part of a coordinated regional approach led by the D.C. Department of Health (DOH), D.C. Hospital Association (DCHA), and D.C. Department of Forensic Science-Public Health Lab (DFS-PHL).

    "CRE is a significant clinical and public health concern, with a potential for widespread and rapid transmission within and between facilities. Our study demonstrates the strength of a collaborative approach within a city or region to determine the prevalence of multi-drug resistant organisms in healthcare facilities," said Roberta DeBiasi, MD, MS, a principal investigator of the study and division chief of infectious diseases at Children's National Medical Center.

    As part of the Healthcare Antibiotic Resistance Prevalence -- DC (HARP-DC) project, the three agencies partnered to conduct a multi-center study of CRE in D.C. Sixteen facilities voluntarily participated, including eight acute care hospitals, two long-term acute care hospitals, one inpatient rehabilitation facility, and five skilled nursing facilities. Each facility conducted bacterial colonization surveillance over a one-to-three-day interval from January to April, 2016. The researchers used the Centers for Disease Control and Prevention CRE surveillance definition and tested all cultures at a single laboratory to ensure consistency.

    Of 1,022 completed tests, 53 samples tested positive for CRE, which corresponds to a prevalence rate of 5.2 percent, confirming that CRE has become endemic in healthcare facilities in Washington, D.C. The median prevalence rate by facility was 2.7 percent, with one facility measuring as high as 29.4 percent of tested patients, indicating the potential for hyperendemicity. Male patients had a significantly higher prevalence of CRE compared to females (7.1 percent vs. 3.7 percent). Adults ages 20-39 (8 percent) also showed higher prevalence than any other age group.

    Of the positive samples, 18 were determined to share genetic similarity with at least one other sample. This revealed the potential transmission of CRE within and between facilities. The ability to determine similarity of strain profiles from culture and molecular testing also enabled the researchers to detect an ongoing outbreak in one facility, further demonstrating the utility of these laboratory techniques for surveillance programs.

    "The study represents a unique collaboration of cutting-edge science, public health concern, dedicated investigators, and selfless patient-volunteers who came together to successfully complete this investigation," said Glenn Wortmann, MD, a principal investigator of the study and section director of infectious diseases at MedStar Washington Hospital Center. "The results will hopefully guide future efforts to control the spread of multi-drug resistant bacteria."

    READ MORE
    ?Addressing chronic disease is an issue of human rights ? that must be our call to arms"
    Richard Horton, Editor-in-Chief The Lancet

    ~~~~ Twitter:@GertvanderHoek ~~~ GertvanderHoek@gmail.com ~~~
Working...
X